This trial is active, not recruiting.

Condition prostate cancer
Treatment galeterone
Phase phase 2
Sponsor Tokai Pharmaceuticals
Start date December 2012
End date December 2016
Trial size 126 participants
Trial identifier NCT01709734, TOK-200-10


A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Dose A - galeterone tablets once daily PO for three months + extension Dose B - galeterone tablets once daily PO for three months + extension Dose C - galeterone tablets once daily PO for three months + extension
galeterone TOK-001
Single dose expansion (from part 1) of galeterone tablets once daily PO for three months + extension
galeterone TOK-001

Primary Outcomes

Confirmation of recommended dose and patient population for Part 2 of the study.
time frame: 3 months
Assessment of efficacy by means of PSA response.
time frame: 3 months

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: 1. Histologically or cytologically confirmed adenocarcinoma of the prostate 2. Ongoing androgen blockade demonstrated by serum testosterone concentration of less than 50 ng/dL 3. Demonstration of progression while on androgen blockade 4. Eastern Cooperative Oncology Group (ECOG) Performance Status <2 Exclusion Criteria: 1. Depending upon patient prior treatment the following apply: - Prior treatment with CYP17 inhibitors or AR antagonists (e.g. abiraterone, TAK-700, ARN-509, ketoconazole*, enzalutamide, or galeterone) - Treatment naïve only - Prior treatment with CYP17 inhibitors (e.g. TAK-700, ketoconazole*) or AR antagonists (e.g. enzalutamide, ARN-509,) or galeterone - abiraterone refractory only - Prior treatment with CYP17 inhibitors (e.g. abiraterone, TAK-700, ketoconazole*) or AR antagonists (e.g. ARN -509) or galeterone - enzalutamide refractory only 2. Prior chemotherapy (unless allowed for some study arms) 3. Treatment with non-steroidal oral antiandrogens within 4 weeks of enrollment 4. Prior use of any chronic systemic glucocorticoids . 5. Prior radiation therapy within 3 weeks and radionuclide therapy within 8 weeks of enrollment 6. Prior treatment with Alpharadin® (Xofigo®) 7. Treatment with anti arrhythmia therapy for ventricular arrhythmia < 4 weeks prior to enrollment 8. Treatment with Coumadin® or other anti-coagulant therapy (except aspirin) < 4 weeks prior to enrollment 9. Severe systemic diseases or active uncontrolled illnesses. 10. Abnormal heart function 11. Liver metastases 12. Brain metastases (unless stable disease >3 mos. by scan without additional CNS-directed therapy) 13. The patient has known allergy to any of the treatment components 14. Any physical or mental condition or social situation that in the opinion of the Investigator may interfere with the patient's ability to comply with the trial procedures 15. History of excessive alcohol consumption 16. Use of any substance known to cause AME

Additional Information

Official title ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
Principal investigator Bruce Montgomery, M.D.
Description This trial will be split into two parts. The purpose of Part 1 will be to confirm dose and target patient population and Part 2 will be expansion of the dose and patient population selected in Part 1. For eligible patients, there will be an optional extension dosing following the completion of Part 1 or Part 2 of the trial. Obtaining of informed consent and screening may be performed up to 28 days prior to enrollment. Each patient will be able to receive his specified regimen for 3 consecutive cycles. Each cycle consists of 28 days (approximately 1 mo.). End of Cycle 3 visit assessments will be used to determine outcome and dosing may continue up to an additional 2 weeks until the results of all assessments are obtained. Eligible patients may continue treatment in an optional extension period following the completion of the primary parts of this trial.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Tokai Pharmaceuticals.
Location data was received from the National Cancer Institute and was last updated in August 2016.